[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355365-105":59,"doc-detail-355365-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clinical-utility-of-circulating-tumour-dna-ctdna-analysis-for-assessing-completeness-of-primary-lesion-resection-and-disease-stage-in-patients-with-melanoma-a-systematic-review","Clinical Utility of Circulating Tumour DNA (ctDNA) Analysis for Assessing Completeness of Primary Lesion Resection and Disease Stage in Patients with Melanoma - A Systematic Review","","Circulating tumour DNA (ctDNA) is evaluated as a biomarker for minimal residual disease, tumour burden, and recurrence risk in melanoma. A systematic review following PRISMA searched PubMed and Web of Science for 2017 to February 2025 studies assessing ctDNA around resection. Fourteen studies with 1077 patients showed that preoperative detection aligns with advanced stage, higher tumour burden, and worse survival. Postoperative ctDNA persistence correlated with recurrence, often months before clinical relapse, while heterogeneity limits immediate clinical translation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinical-utility-of-circulating-tumour-dna-ctdna-analysis-for-assessing-completeness-of-primary-lesion-resection-and-disease-stage-in-patients-with-melanoma-a-systematic-review/355365/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinical-utility-of-circulating-tumour-dna-ctdna-analysis-for-assessing-completeness-of-primary-lesion-resection-and-disease-stage-in-patients-with-melanoma-a-systematic-review/355365.png","ImageObject",300,407,{"name":92,"@type":93},"Jake","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical purpose does ctDNA analysis serve in melanoma management?","Question",{"text":112,"@type":113},"ctDNA analysis can detect minimal residual disease, estimate tumour burden, and predict recurrence, including when used around the time of resection.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were eligible studies selected in this systematic review?",{"text":117,"@type":113},"Studies were selected using PRISMA guidance and included those that measured ctDNA before, during, or after melanoma resection; studies without perioperative ctDNA assessment or focused only on immunotherapy efficacy were excluded.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the review find about ctDNA after surgery?",{"text":121,"@type":113},"Persisting postoperative ctDNA was strongly associated with recurrence and could be detected months before clinical relapse, while clearance of ctDNA in disease-free patients was often seen within weeks.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355365,1790165334,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962084928904,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Systematic Review  \nClinical Utility of Circulating Tumour DNA (ctDNA) Analysis for Assessing Completeness of Primary Lesion Resection and Disease Stage in Patients with Melanoma: A Systematic Review  \nMonika Wojarska 1,*, Klaudia Kokot 2,3, *, Paulina Bernecka 2, Aleksandra Kierczak 2, Natalia Sitkiewicz 2, Aleksandra Wakszy ´nska 2, Tomasz Wichowski 2, Weronika Skok 2, Milena Matwiejczuk 2, Wiktor Lijewski 2 and Jerzy Jankau 1  \nAcademic Editor: Andrzej Slominski  \nReceived: 3 January 2026  \nRevised: 16 February 2026  \nAccepted: 23 February 2026  \nPublished: 28 February 2026  \nCopyright: © 2026 by the authors. Published by MDPI on behalf of the Lithuanian University of Health Sciences. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Plastic Surgery Department, University Clinical Center in Gda ´nsk, 80-952 Gda ´nsk, Poland; [jerzy.jankau@gumed.edu.pl](jerzy.jankau@gumed.edu.pl)  \n2 Students’ Scientific Circle of Plastic Surgery, Plastic Surgery Department, Medical University of Gda ´nsk, 80-210 Gda ´nsk, Poland; [pauline.bernecka@gmail.com](pauline.bernecka@gmail.com) (P.B.); [olakierczak@gumed.edu.pl](olakierczak@gumed.edu.pl) (A.K.); [natalia.sitkiewicz@gumed.edu.pl](natalia.sitkiewicz@gumed.edu.pl) (N.S.); [wakszynska@gumed.edu.pl](wakszynska@gumed.edu.pl) (A.W.); [tomasz.wichowski@gumed.edu.pl](tomasz.wichowski@gumed.edu.pl) (T.W.); [skok.wera@gumed.edu.pl](skok.wera@gumed.edu.pl) (W.S.); [milena.matwiejczuk@gumed.edu.pl](milena.matwiejczuk@gumed.edu.pl) (M.M.); [wiktor.lijewski@gumed.edu.pl](wiktor.lijewski@gumed.edu.pl) (W.L.)  \n3 Scientific Circle of Neurotraumatology, Department of Emergency Medicine, Medical University of Gda ´nsk, 80-210 Gda ´nsk, Poland  \n* [Correspondence: monika.wojarska@gumed.edu.pl](Correspondence: monika.wojarska@gumed.edu.pl) (M.W.); [klaudia.kokot@gumed.edu.pl](klaudia.kokot@gumed.edu.pl) (K.K.)  \nAbstract  \nBackground and Objectives: Melanoma is an aggressive cutaneous malignancy with a high recurrence rate even after complete resection. Circulating tumour DNA (ctDNA) has emerged as a promising biomarker for detecting minimal residual disease (MRD), assessing tumour burden, and predicting recurrence. This study aims to evaluate the clinical utility of ctDNA analysis in determining completeness of melanoma resection and disease staging. Materials and Methods: A systematic review was conducted in accordance with PRISMA guidelines, searching PubMed and Web of Science for studies published between January 2017 and February 2025 . Eligible studies assessed ctDNA before, during, or after melanoma resection to evaluate surgical completeness and staging. Studies without perioperative ctDNA assessment or which focused solely on immunotherapy efficacy were excluded. Results: Fourteen studies with 1077 patients met the inclusion criteria. Preoperative ctDNA detection correlated with advanced stage, greater tumour burden, and poorer survival. Postoperative ctDNA persistence was strongly associated with recurrence, often detectable months before clinical relapse. In most patients remaining disease-free, ctDNA cleared within weeks after surgery. ctDNA levels reflected metastatic spread, though sensitivity was lower for brain lesions. Across studies, undetectable postoperative ctDNA was consistently linked to longer recurrence-free survival. Conclusions: Perioperative ctDNA analysis shows promise as a prognostic biomarker for detecting residual disease and anticipating relapse in melanoma. However, heterogeneity in patient cohorts, study design, and ctDNA detection methods limits immediate clinical application. Large, standardized prospective trials are needed to validate ctDNA for perioperative management.  \nKeywords: melanoma; circulating tumour DNA; ctDNA; cell-free DNA; cfDNA  \n1. Introduction  \n1.1. Melanoma  \nMelanoma is the most aggressive form of skin cancer associated wit","cbCaigcSfuO8AmDs","https://ap.wps.com/l/cbCaigcSfuO8AmDs","pdf",550335,14,"English","# Introduction\n## Melanoma\n# Abstract\n## Background and Objectives\n## Materials and Methods\n## Results\n## Conclusions","[{\"question\":\"What clinical purpose does ctDNA analysis serve in melanoma management?\",\"answer\":\"ctDNA analysis can detect minimal residual disease, estimate tumour burden, and predict recurrence, including when used around the time of resection.\"},{\"question\":\"How were eligible studies selected in this systematic review?\",\"answer\":\"Studies were selected using PRISMA guidance and included those that measured ctDNA before, during, or after melanoma resection; studies without perioperative ctDNA assessment or focused only on immunotherapy efficacy were excluded.\"},{\"question\":\"What did the review find about ctDNA after surgery?\",\"answer\":\"Persisting postoperative ctDNA was strongly associated with recurrence and could be detected months before clinical relapse, while clearance of ctDNA in disease-free patients was often seen within weeks.\"}]","Clinical Utility of Circulating Tumour DNA (ctDNA) Analysis for Assessing Completeness of Primary Lesion Resection and Disease Stage in Patients with Melanoma - A Systematic Review | PDF",1790118075,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e9c380ace9e7155c045b6fff2936b439.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1fcb69c37f70c48221d4fcf302f90906.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/719f792a427f65189c797ce243238a18.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4dfa93be050e831249ead2ae00568483.webp",980,1385]